Hairy cell leukemia treated initially with purine analogs: A retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1007-1012

  López Rubio, Montserrat ^a   Da Silva, Carolina ^b   Loscertales, Javier ^c   Seri, Cristina ^d   Baltasar, Patricia ^e   Colado, Enrique ^f   Pérez Fernández, Inmaculada ^g   Osma, Mar ^h   Gomis, Federico ⁱ   González, Marcos ^j   Jarque, Isidro ⁱ   Vargas, Manuel ^k   Monzó, Encarnación ^l   Monteagudo, Dolores ^m   Orts, Maria Isabel ⁿ   Pardal, Emilia ^o   Carbonell, Félix ^p   Perez Calvo, Cesar ^q   Garcia Marco, Jose A ^r  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^h HOSPITAL MORALES MESEGUER   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j UNIVERSITY OF SALAMANCA   (Spain)

^k Hospital Comarcal de Jarrio   (Spain)

^l HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^m HOSPITAL DE MÓSTOLES   (Spain)

ⁿ HOSPITAL DE SAGUNTO   (Spain)

^o HOSPITAL VIRGEN DEL PUERTO   (Spain)

^p HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^q Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^r HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

more..

Author keywords

Cladribine; Hairy cell leukemia; Pentostatin

Indexed keywords

CLADRIBINE; HEMOGLOBIN; INTERFERON; MONOCLONAL ANTIBODY; PENTOSTATIN; PURINE DERIVATIVE; RITUXIMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAIRY CELL LEUKEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SPLENECTOMY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT FREE INTERVAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; LEUKEMIA, HAIRY CELL; MORTALITY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; PENTOSTATIN; SPLENECTOMY; TREATMENT OUTCOME;

EID: 84899758069     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.827187     Document Type: Article

References (31)

1. Staines A, Cartwright RA. Hairy cell leukaemia: Descriptive epidemiology and a case-control study. Br J Haematol 1993; 85: 714-717.
2. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairycell leukemia. N Engl J Med 2011; 364: 2305-2315.
3. Cannon T, Mobarek D, Wegge J, et al. Hairy cell leukemia: Current concepts. Cancer Invest 2008; 26: 860-865.
4. Berman E, Heller G, Kempin S, et al. Incidence of response and long-Term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 1990; 75: 839-845.
5. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 1995; 13: 974-982.
6. Federico M, Frassoldati A, Lamparelli T, et al. Long-Term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Ann Oncol 1994; 5: 725-731.
7. Chadha P, Rademaker A W, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): Longterm follow-up of the Northwestern University experience. Blood 2005; 106: 241-246.
8. Else M, Dearden CE, Matutes E, et al. Long-Term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145: 733-740.
9. Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21: 891-896.
10. Jehn U, Bartl R, Dietzfelbinger H, et a l. A n update: 12-year followup of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004; 18: 1476-1481.
11. Grever M R. H ow I treat hairy cell leukemia. B lood 2 010; 1 15: 21-28.
12. Benz R, Stussi G, Fehr J. Interferon as an alternative to purine analogues in the treatment of hairy cell leukaemia. Br J Haematol 2010; 148: 664-665.
13. Seymour JF, Estey EH, Keating MJ, et al. Response to interferonalpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 1995; 9: 929-932.
14. Katayama I, Yang JP. Reassessment of a cytochemical test for differential diagnosis of leukemic reticuloendotheliosis. Am J Clin Pathol 1977; 68: 268-272.
15. Polliack A, Tadmor T. S urface topography of hairy cell leukemia cells compared to other leukemias as seen by scanning electron microscopy. Leuk Lymphoma 2011; 52(Suppl. 2): 14-17.
16. Consensus resolution: Proposed criteria for evaluation of response to treatment in hairy cell leukaemia. Leukemia 1987; 1: 405.
17. Maloisel F, Benboubker L, Gardembas M, et al. Long-Term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003; 17: 45-51.
18. Saven A, Burian C, Koziol JA, et al. Long-Term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-1926.
19. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-Term followup of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96: 2981-2986.
20. Rafel M, Cervantes F, Beltran JM, et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: Results of a Spanish collaborative study of 80 patients. Cancer 2000; 88: 352-357.
21. Zinzani PL, Tani M, Marchi E, et al. Long-Term follow-up of frontline treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004; 89: 309-313.
22. Jehn U, Bartl R, Dietzfelbinger H, et a l. A n update: 12-year followup of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004; 18: 1476-1481.
23. Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: Long-Term follow-up of the Northwestern University experience. Blood 1996; 88: 1954-1959.
24. Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: A report of 979 patients. J Clin Oncol 1998; 16: 3007-3015.
25. Jansen J, Hermans J. Clinical staging system for hairy-cell leukemia. Blood 1982; 60: 571-577.
26. Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84: 4310-4315.
27. Matutes E, Meeus P, McLennan K, et al. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: A long-Term follow-up study. Br J Haematol 1997; 98: 375-383.
28. Bengio R, Narbaitz MI, Sarmiento MA, et al. Comparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemia. Haematologica 2000; 85: 1227-1229.
29. Sausville JE, Salloum RG, Sorbara L, et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 2003; 119: 213-217.
30. Tallman M S, Hakimian D, Kopecky K J, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999; 5: 1665-1670.
31. Wheaton S, Tallman MS, Hakimian D, et al. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996; 87: 1556-1560.